• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症筛查中盲法和统一死因验证:对前列腺癌筛查试验结果的重大影响?

Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?

机构信息

Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

出版信息

Eur J Cancer. 2010 Nov;46(17):3061-7. doi: 10.1016/j.ejca.2010.09.026.

DOI:10.1016/j.ejca.2010.09.026
PMID:21047587
Abstract

BACKGROUND

To assess the agreement between the causes of death assigned by a blinded and uniform review panel of the Rotterdam section of the European Randomised Study of Screening for Prostate Cancer and the official vital statistics and to explore the possible effect of the use of either of these two sources on the outcome of the screening trial.

METHODS

A total of 670 deaths amongst men with prostate cancer, reviewed by the causes of death committee (CODC) up to 31st December 2006 were included in this study. The kappa statistics with confidence intervals (CI), sensitivity and specificity of the official statistics were determined, with the CODC considered the gold standard. The rate ratio (RR) and 95% confidence intervals (95% CI) for prostate cancer mortality, official statistics relative to CODC, were calculated following the Mantel-Haenszel procedure.

RESULTS

The overall concordance and the kappa between official statistics and the CODC were 90.6% and 0.76 (0.71-0.82), remaining comparable when only the CODC category definitely prostate cancer was applied, with the sensitivity of official statistics increasing from 88.3% to 91.3% and specificity hardly changing (91.3% and 90.5%). High specificity and lower sensitivity is observed in the screening arm, whilst the opposite was seen in the control arm in men aged 55-69 and 70-74 years at entry. Considerable lower false positive rate was seen for both age groups in the screening arm (3.9% and 4.7%) compared to the control arm (8.4% and 14.3%). A statistically significant excess of prostate cancer death was observed for the official statistics in the age group 70-74 years, 1.53 (1.07-2.19), whilst it was not significant for men aged 55-69 at entry, 1.06 (0.83-1.36).

CONCLUSION

In the Rotterdam ERSPC section, official statistics tended to overreport prostate cancer as an underlying cause of death, particularly in the age group 70-plus in the control arm, which would overestimate the true effect in favour of screening.

摘要

背景

评估由鹿特丹欧洲前列腺癌筛查随机研究分部的盲法和统一审查小组分配的死因与官方生命统计数据之间的一致性,并探讨使用这两个来源中的任何一个对筛查试验结果的可能影响。

方法

本研究共纳入了截至 2006 年 12 月 31 日由死因委员会(CODC)审查的 670 例前列腺癌死亡患者。使用 Kappa 统计量(置信区间[CI])、敏感性和特异性来确定官方统计数据的一致性,将 CODC 视为金标准。使用 Mantel-Haenszel 程序计算相对于 CODC 的官方统计数据的前列腺癌死亡率的率比(RR)和 95%置信区间(95%CI)。

结果

官方统计数据与 CODC 之间的总体一致性和 Kappa 值分别为 90.6%和 0.76(0.71-0.82),当仅应用 CODC 确定的前列腺癌类别时,结果仍然相似,官方统计数据的敏感性从 88.3%增加到 91.3%,特异性几乎没有变化(91.3%和 90.5%)。在年龄为 55-69 岁和 70-74 岁的入组人群中,筛查组的特异性较高而敏感性较低,而对照组则相反。在筛查组中,两个年龄组的假阳性率均显著低于对照组(分别为 3.9%和 4.7%)(分别为 8.4%和 14.3%)。在年龄组为 70-74 岁的人群中,官方统计数据显示前列腺癌死亡的超额风险显著增加,为 1.53(1.07-2.19),而在年龄组为 55-69 岁的人群中,该风险不显著,为 1.06(0.83-1.36)。

结论

在鹿特丹 ERSPC 分部,官方统计数据倾向于过度报告前列腺癌作为主要死因,特别是在对照组的 70 岁以上年龄组中,这将高估筛查的真实效果。

相似文献

1
Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?癌症筛查中盲法和统一死因验证:对前列腺癌筛查试验结果的重大影响?
Eur J Cancer. 2010 Nov;46(17):3061-7. doi: 10.1016/j.ejca.2010.09.026.
2
PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.前列腺特异性抗原水平和各中心的癌症检出率在欧洲前列腺癌筛查随机研究中。
Eur J Cancer. 2010 Nov;46(17):3053-60. doi: 10.1016/j.ejca.2010.09.012.
3
Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).前列腺癌的检测:欧洲前列腺癌筛查随机研究(ERSPC)的影响
Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3.
4
Epilogue: different approaches for prostate cancer screening in the EU?结语:欧盟前列腺癌筛查的不同方法?
Eur J Cancer. 2010 Nov;46(17):3120-5. doi: 10.1016/j.ejca.2010.09.038.
5
Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.前列腺癌筛查随机试验之前及期间的前列腺特异性抗原检测和直肠指检:欧洲前列腺癌筛查随机研究,鹿特丹
J Urol. 2000 Oct;164(4):1216-20.
6
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.在欧洲前列腺癌筛查随机研究中,使用前列腺特异性抗原进行前列腺癌筛查。
Eur J Cancer. 2010 Nov;46(17):3109-19. doi: 10.1016/j.ejca.2010.09.031.
7
Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.前列腺癌筛查与死亡率:近期随机对照临床试验的比较
Urol Oncol. 2010 May-Jun;28(3):233-6. doi: 10.1016/j.urolonc.2009.11.011. Epub 2010 Jan 25.
8
Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.前列腺特异性抗原检测与前列腺癌筛查:基层医疗医生的最新资讯
Can J Urol. 2010 Feb;17 Suppl 1:18-25.
9
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.筛查和临床检出前列腺癌的前列腺癌死亡率:估计筛查的获益。
Eur J Cancer. 2010 Jan;46(2):377-83. doi: 10.1016/j.ejca.2009.09.008. Epub 2009 Oct 3.
10
[The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].[前列腺癌筛查的不合理性及其相关研究的伦理问题]
Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):966-71.

引用本文的文献

1
Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer.欧洲前列腺癌筛查随机研究中的干预相关死亡
Eur Urol Open Sci. 2021 Oct 28;34:27-32. doi: 10.1016/j.euros.2021.09.014. eCollection 2021 Dec.
2
Impact of cause of death adjudication on the results of the European prostate cancer screening trial.死因判定对欧洲前列腺癌筛查试验结果的影响。
Br J Cancer. 2017 Jan 3;116(1):141-148. doi: 10.1038/bjc.2016.378. Epub 2016 Nov 17.
3
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
前列腺癌筛查的绝对效果:欧洲前列腺癌筛查随机研究中各中心的利弊权衡
Clin Cancer Res. 2016 Jan 1;22(1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. Epub 2015 Aug 19.
4
Prostate cancer: net survival and cause-specific survival rates after multiple imputation.前列腺癌:多次插补后的净生存率和特定病因生存率
BMC Med Res Methodol. 2015 Jul 28;15:54. doi: 10.1186/s12874-015-0048-4.
5
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).在癌症筛查试验中提交给终点委员会用于死因判定的信息标准化——从CAP(前列腺癌PSA检测的整群随机试验)中吸取的经验教训
BMC Med Res Methodol. 2015 Jan 23;15:6. doi: 10.1186/1471-2288-15-6.